The CD52 antigen and development of the CAMPATH antibodies

Cytotherapy

Volumn 3, Issue 3, 2001, Pages 137-143

  Hale, G ^a  

^a Therapeutic Antibody Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CAMPATH 1 IMMUNOGLOBULIN G; CAMPATH 1 IMMUNOGLOBULIN M; CD52 ANTIGEN; COMPLEMENT; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN M ANTIBODY; METHYLPREDNISOLONE; UNCLASSIFIED DRUG; CAMPATH 1M; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEVER; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE; LYSIS; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; REVIEW; RIGOR; SPERM; STRUCTURE ANALYSIS; TRANSPLANTATION; ANIMAL; DRUG DESIGN; DRUG EFFECT; IATROGENIC DISEASE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MAMMAL; METHODOLOGY; PATHOPHYSIOLOGY; RAT; SPERMATOZOON; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; DRUG DESIGN; GLYCOPROTEINS; GRAFT VS HOST DISEASE; HUMAN; IMMUNOSUPPRESSION; INFECTION; LYMPHOCYTES; MALE; MAMMALS; RATS; SPERMATOZOA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0034765991     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532401753174098     Document Type: Review

References (51)

1. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement
2. Structure of the CAMPATH-1 antigen, a GPI-anchored glycoprotein which is an exceptionally good target for complement lysis
3. Primary structure of CD52
4. Efficient complement mediated lysis of cells containing the CAMPATH-1 antigen
5. Male-specific modification of human CD52
6. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils
7. The GPI-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa
8. Cell to cell transfer of glycosylphosphatidylinositol-anchored membrane proteins during sperm maturation
9. + cells and progenitor cell recoveries
10. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
11. The repopulation capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in rhesus monkeys
12. -/lo fetal and adult bone marrow
13. + recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in bone marrow and PBSC collections: Comparison with CAMPATH-1M and CAMPATH-1G
14. Risks of developing EBV-related lymphoproliferative disorders following T cell depleted marrow transplants
15. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
16. Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor
17. Gene expression in the dog epididymis: A model for human epididymal function
18. CD52 is the 'major maturation-associated' sperm membrane antigen
19. Identification and gene cloning of a new phosphatidylinositol-linked antigen expressed on mature lymphocytes. Down-regulation by lymphocyte activation
20. Elimination of graft versus host disease by in vitro depletion of alloreactive lymphocytes using a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)
21. The current status of T cell depleted allogeneic stem cell transplants in adult patients with acute myeloid leukaemia: A review
22. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: The depletion of T-cell subsets in vitro and in vivo
23. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans
24. Isolation of low-frequency class-switch variants from rat hybrid myelomas
25. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
26. CAMPATH-1 monoclonal antibodies in bone marrow transplantation
27. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft versus host disease and graft rejection
28. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukemia in second complete remission
29. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials
30. T-cell depletion by exposure to CAMPATH-1G in vitro prevents graft-versus-host disease
31. Bone marrow transplantation for chronic myeloid leukaemia with volunteer unrelated donor using ex vivo or in vivo T cell depletion: Major prognostic impact of HLA class I identity between donor and recipient
32. Reshaping human antibodies for therapy
33. CD52 antibodies for prevention of graft versus host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
34. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-CAMPATH conditioning: An affective regimen with low procedure related toxicity
35. Cross-linking the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes
36. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells
37. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
38. Ex-vivo whole blood cultures for prediction cytokine-release syndrome: Dependence on target antigen and antibody isotype
39. A humanized monovalent CD3 antibody which can activate homologous complement
40. Elimination of the immunogenicity of therapeutic antibodies
41. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
42. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H
43. Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection
44. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis
45. Immunosuppressive toxicity of CAMPATH-1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma
46. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia-graft-versus-host disease and graft-versus-leukemia effect
47. Persistent lymphopenia secondary to lymphocytotoxic monoclonal antibody therapy of rheumatoid arthritis is not associated with opportunistic infections during seven years of follow-up
48. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
49. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
50. CAMPATH-1H allows low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients
51. From laboratory to clinic: The story of CAMPATH-1